BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24414130)

  • 1. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.
    de Dueñas EM; Hernández AL; Zotano AG; Carrión RM; López-Muñiz JI; Novoa SA; Rodríguez AL; Fidalgo JA; Lozano JF; Gasión OB; Carrascal EC; Capilla AH; López-Barajas IB; Mateu MM; de Ceballos Reyna MH; Ferrando AO; Jañez NM; Ballerini VC; Torres AA; Catalán G; Sáenz JA; Menjón S; González-Angulo AM
    Breast Cancer Res Treat; 2014 Feb; 143(3):507-15. PubMed ID: 24414130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
    Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
    Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
    Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
    Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
    J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
    Thompson AM; Jordan LB; Quinlan P; Anderson E; Skene A; Dewar JA; Purdie CA;
    Breast Cancer Res; 2010; 12(6):R92. PubMed ID: 21059212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
    Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer.
    Lv H; Niu L; Zhang M; Zeng H; Zhao S; Yan M
    Chin Med J (Engl); 2022 Sep; 135(17):2076-2082. PubMed ID: 35916549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
    Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
    Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
    Ma XM; Han YW; Zhang J; Cui WJ; Wang X
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
    Shen J; Xu L; Shi J; Zhao L; Shi S; Feng J; Han X; Shi Y; Wei Q; Wang D; Sun M; Mi X; Teng Y
    Oncol Res Treat; 2020; 43(11):620-627. PubMed ID: 32966998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
    Jensen JD; Knoop A; Ewertz M; Laenkholm AV
    Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
    Nguyen TH; Nguyen VH; Nguyen TL; Qiuyin C; Phung TH
    Biomed Res Int; 2019; 2019():7391237. PubMed ID: 31583246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
    Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
    Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
    Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
    Simmons C; Miller N; Geddie W; Gianfelice D; Oldfield M; Dranitsaris G; Clemons MJ
    Ann Oncol; 2009 Sep; 20(9):1499-1504. PubMed ID: 19299408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.